The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis

Gil Benedek, Roberto Meza-Romero, Dennis Bourdette, Arthur A. Vandenbark

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Applying different technologies to monitor disease activity and treatment efficacy are essential in a complex disease such as multiple sclerosis. Combining current assays with flow cytometry could create a powerful tool for such analyses. The cell surface expression level of CD74, theMHC class II invariant chain, is a potential disease biomarker that could be monitored by FACS analysis in order to assess disease progression and the clinical efficacy of partial MHC class II constructs in treatingMS. These constructs, which can bind to and down-regulate CD74 cell-surface expression on monocytes and inhibitmacrophagemigration inhibitory factor (MIF) effects, can reverse clinical and histological signs of EAE. These properties of partial class II constructs are highly compatible with a flow cytometry approach for monitoring CD74 expression as a possible biomarker for disease activity/ progression and as a treatment response marker.

Original languageEnglish (US)
Article numberA002
Pages (from-to)877-884
Number of pages8
JournalMetabolic brain disease
Issue number4
StatePublished - Aug 1 2015


  • CD74
  • EAE
  • Flow cytometry
  • Multiple sclerosis
  • Partial MHC class II constructs

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Neurology
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis'. Together they form a unique fingerprint.

Cite this